SCHEMBL5404078

SCHEMBL5404078

O=C(NS(=O)(=O)/C=C/c1ccccc1Cl)c1ccc(F)cc1C(F)(F)F

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGES2 Q9H7Z7 6/20 0.45
FLT4 P35916 3/20 0.42
FLT1 P17948 2/20 0.42
KDR P35968 2/20 0.42
NFE2L2 Q16236 2/20 0.41
NPC1 O15118 2/20 0.40
MAPT P10636 2/20 0.40
RAB9A P51151 2/20 0.40
HPGD P15428 1/20 0.40
HTT P42858 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
MAOB P27338 1/20 0.37
GAA P10253 1/20 0.37
AURKA O14965 1/20 0.37
CHEK2 O96017 1/20 0.37
CSF1R P07333 1/20 0.37
RET P07949 1/20 0.37
ABL2 P42684 1/20 0.37
BLK P51451 1/20 0.37
LIMK1 P53667 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5404086 1.00 PTGES2 (0.45) PTGES2FLT4FLT1KDRNFE2L2
SCHEMBL5409663 0.89 FLT1 (0.55) PTGES2FLT4FLT1KDRNFE2L2
SCHEMBL5404009 0.84 PTGES2 (0.43) PTGES2FLT4FLT1KDRNFE2L2
SCHEMBL5403998 0.84 PTGES2 (0.43) PTGES2FLT4FLT1KDRNFE2L2
SCHEMBL4620014 0.84 KMT2A (0.47) PTGES2FLT4FLT1KDRHTT
SCHEMBL4620007 0.84 KMT2A (0.47) PTGES2FLT4FLT1KDRHTT
SCHEMBL5406598 0.82 FLT1 (0.51) PTGES2FLT4FLT1KDRNPC1
SCHEMBL5406605 0.82 FLT1 (0.51) PTGES2FLT4FLT1KDRNPC1
SCHEMBL5408883 0.82 PTGES2 (0.50) PTGES2FLT4FLT1KDRNFE2L2
SCHEMBL5408893 0.82 PTGES2 (0.50) PTGES2FLT4FLT1KDRNFE2L2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7208526-B2 For example, (E)-2-(4-Chloro-phenyl)-ethenesulfonic acid 2,4-dichloro-benzoylamide; for use in the control or prevention of illnesses such as cancer; antitumor agents HOFFMANN-LA ROCHE INC. (US) 2007-04-24 US claimed
US-20060270874-A1 Styrylsulfonamides HOFFMANN-LA ROCHE INC. 2006-11-30 US claimed
US-7208526-B2 For example, (E)-2-(4-Chloro-phenyl)-ethenesulfonic acid 2,4-dichloro-benzoylamide; for use in the control or prevention of illnesses such as cancer; antitumor agents HOFFMANN-LA ROCHE INC. (US) 2007-04-24 US disclosed
US-20060270874-A1 Styrylsulfonamides HOFFMANN-LA ROCHE INC. 2006-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060270874-A1 Styrylsulfonamides STS, SULT1E1, BRCA1 PTGES2 3551/4885FLT4 4438/4885FLT1 4126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.